BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guzman G, Alagiozian-Angelova V, Layden-Almer JE, Layden TJ, Testa G, Benedetti E, Kajdacsy-Balla A, Cotler SJ. p53, Ki-67, and serum alpha feto-protein as predictors of hepatocellular carcinoma recurrence in liver transplant patients. Mod Pathol 2005;18:1498-503. [PMID: 16007066 DOI: 10.1038/modpathol.3800458] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Subastri A, Suyavaran A, Preedia Babu E, Nithyananthan S, Barathidasan R, Thirunavukkarasu C. Troxerutin with copper generates oxidative stress in cancer cells: Its possible chemotherapeutic mechanism against hepatocellular carcinoma. J Cell Physiol 2018;233:1775-90. [PMID: 28628229 DOI: 10.1002/jcp.26061] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
2 Chung C, Al Ali J, Owen DA, Weiss AA, Yoshida EM, Tai IT. A rare case of isolated duodenal metastases from hepatocellular carcinoma associated with p53 and ki-67 expression: a case report. Cases J 2009;2:9344. [PMID: 20062599 DOI: 10.1186/1757-1626-2-9344] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
3 Abu-Zeid EH, Abdel Fattah DM, Arisha AH, Ismail TA, Alsadek DM, Metwally MMM, El-Sayed AA, Khalil AT. Protective prospects of eco-friendly synthesized selenium nanoparticles using Moringa oleifera or Moringa oleifera leaf extract against melamine induced nephrotoxicity in male rats. Ecotoxicol Environ Saf 2021;221:112424. [PMID: 34174736 DOI: 10.1016/j.ecoenv.2021.112424] [Reference Citation Analysis]
4 Yu L, Dai Z, Wang Z, Fan J, Zhou J. Prognostic indicators for tumor recurrence after liver transplantation in hepatocellular carcinoma and related molecular targeted therapy. Oncology. 2011;81 Suppl 1:116-122. [PMID: 22212945 DOI: 10.1159/000333273] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
5 Marshall AE, Rushbrook SM, Vowler SL, Palmer CR, Davies RJ, Gibbs P, Davies SE, Coleman N, Alexander GJ. Tumor recurrence following liver transplantation for hepatocellular carcinoma: role of tumor proliferation status. Liver Transpl. 2010;16:279-288. [PMID: 20209638 DOI: 10.1002/lt.21993] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
6 Zakaria Y, Rahmat A, Pihie AH, Abdullah NR, Houghton PJ. Eurycomanone induce apoptosis in HepG2 cells via up-regulation of p53. Cancer Cell Int 2009;9:16. [PMID: 19508737 DOI: 10.1186/1475-2867-9-16] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
7 Mourad W, Khalaf H, Tulbah A, Al Omari M, Al Mana H, Neimatallah M. Clinicopathologic features of hepatic neoplasms in explanted livers: a single institution experience. Ann Saudi Med 2007;27:437-41. [PMID: 18059117 DOI: 10.5144/0256-4947.2007.437] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
8 Khalil MI, Ibrahim MM, El-Gaaly GA, Sultan AS. Trigonella foenum (Fenugreek) Induced Apoptosis in Hepatocellular Carcinoma Cell Line, HepG2, Mediated by Upregulation of p53 and Proliferating Cell Nuclear Antigen. Biomed Res Int 2015;2015:914645. [PMID: 26557712 DOI: 10.1155/2015/914645] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
9 Yang A, Fan H, Zhao Y, Chen X, Zhu Z, Zha X, Zhao Y, Chai X, Li J, Tu P, Hu Z. An immune-stimulating proteoglycan from the medicinal mushroom Huaier up-regulates NF-κB and MAPK signaling via Toll-like receptor 4. J Biol Chem 2019;294:2628-41. [PMID: 30602571 DOI: 10.1074/jbc.RA118.005477] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
10 Fan Y, Yu Y, Wang X, Hu M, Hu C. Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma. BMC Med Imaging 2021;21:100. [PMID: 34130644 DOI: 10.1186/s12880-021-00633-0] [Reference Citation Analysis]
11 Dai Z, Liu YK, Cui JF, Shen HL, Chen J, Sun RX, Zhang Y, Zhou XW, Yang PY, Tang ZY. Identification and analysis of altered alpha1,6-fucosylated glycoproteins associated with hepatocellular carcinoma metastasis. Proteomics. 2006;6:5857-5867. [PMID: 17068759 DOI: 10.1002/pmic.200500707] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
12 Hakeem AR, Young RS, Marangoni G, Lodge JP, Prasad KR. Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35:987-999. [PMID: 22429190 DOI: 10.1111/j.1365-2036.2012.05060.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 40] [Article Influence: 1.9] [Reference Citation Analysis]
13 Tennakoon AH, Izawa T, Wijesundera KK, Katou-Ichikawa C, Tanaka M, Golbar HM, Kuwamura M, Yamate J. Analysis of glial fibrillary acidic protein (GFAP)-expressing ductular cells in a rat liver cirrhosis model induced by repeated injections of thioacetamide (TAA). Exp Mol Pathol 2015;98:476-85. [PMID: 25758201 DOI: 10.1016/j.yexmp.2015.03.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zhan P, Ji YN. Prognostic significance of TP53 expression for patients with hepatocellular carcinoma: a meta-analysis. Hepatobiliary Surg Nutr. 2014;3:11-17. [PMID: 24696834 DOI: 10.3978/j.issn.2304-3881.2014.01.03] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
15 Bai Y, Lian Y, Chen X, Wu J, Lai J, Qiu F, Zhou S, Zhu Z, Tian Y, Wang Y, Yang Y, Yan M. Immunohistochemical Signature Add Prognostic Value in Patients With Early and Intermediate Hepatocellular Carcinoma Underwent Curative Liver Resection. Front Oncol 2020;10:616263. [PMID: 33585243 DOI: 10.3389/fonc.2020.616263] [Reference Citation Analysis]
16 Pommergaard HC, Burcharth J, Rosenberg J, Rasmussen A. Serologic and molecular biomarkers for recurrence of hepatocellular carcinoma after liver transplantation: A systematic review and meta-analysis. Transplant Rev (Orlando). 2016;30:171-177. [PMID: 27118303 DOI: 10.1016/j.trre.2016.03.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
17 Johal H, Scott GM, Jones R, Camaris C, Riordan S, Rawlinson WD. Mouse mammary tumour virus-like virus (MMTV-LV) is present within the liver in a wide range of hepatic disorders and unrelated to nuclear p53 expression or hepatocarcinogenesis. J Hepatol 2009;50:548-54. [PMID: 19168254 DOI: 10.1016/j.jhep.2008.10.026] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
18 Libbrecht L. Hepatic progenitor cells in human liver tumor development. World J Gastroenterol 2006;12:6261-5. [PMID: 17072946 DOI: 10.3748/wjg.v12.i39.6261] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
19 Chauhan R, Lahiri N. Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma. Biomark Cancer. 2016;8:37-55. [PMID: 27398029 DOI: 10.4137/bic.s34413] [Cited by in Crossref: 26] [Cited by in F6Publishing: 43] [Article Influence: 5.2] [Reference Citation Analysis]
20 Burkhart RA, Ronnekleiv-Kelly SM, Pawlik TM. Personalized therapy in hepatocellular carcinoma: Molecular markers of prognosis and therapeutic response. Surg Oncol. 2017;26:138-145. [PMID: 28577719 DOI: 10.1016/j.suronc.2017.01.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
21 Baiomy AA, Attia HF, Soliman MM, Makrum O. Protective effect of ginger and zinc chloride mixture on the liver and kidney alterations induced by malathion toxicity. Int J Immunopathol Pharmacol 2015;28:122-8. [DOI: 10.1177/0394632015572083] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
22 Ji YN, Wang Q, Xue J. TP53 immunohistochemical expression is associated with the poor outcome for hepatocellular carcinoma: evidence from a meta-analysis. Tumour Biol 2014;35:1653-9. [PMID: 24078450 DOI: 10.1007/s13277-013-1228-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
23 Fartoux L, Decaens T. Contribution of biomarkers and imaging in the management of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2011;35 Suppl 1:S21-S30. [PMID: 21742297 DOI: 10.1016/s2210-7401(11)70004-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
24 Benten D, Keller G, Quaas A, Schrader J, Gontarewicz A, Balabanov S, Braig M, Wege H, Moll J, Lohse AW, Brummendorf TH. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia 2009;11:934-44. [PMID: 19724687 DOI: 10.1593/neo.09664] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 3.6] [Reference Citation Analysis]
25 Minagawa T, Yamazaki K, Masugi Y, Tsujikawa H, Ojima H, Hibi T, Abe Y, Yagi H, Kitago M, Shinoda M, Itano O, Kitagawa Y, Sakamoto M. Activation of extracellular signal‐regulated kinase is associated with hepatocellular carcinoma with aggressive phenotypes. Hepatol Res 2020;50:353-64. [DOI: 10.1111/hepr.13445] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
26 Basturk O, Farris AB, Adsay NV. Immunohistology of the Pancreas, Biliary Tract, and Liver. Diagnostic Immunohistochemistry. Elsevier; 2011. pp. 541-92. [DOI: 10.1016/b978-1-4160-5766-6.00019-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
27 Guzman G, Cotler SJ, Lin AY, Maniotis AJ, Folberg R. A pilot study of vasculogenic mimicry immunohistochemical expression in hepatocellular carcinoma. Arch Pathol Lab Med 2007;131:1776-81. [PMID: 18081435 DOI: 10.5858/2007-131-1776-APSOVM] [Cited by in Crossref: 8] [Cited by in F6Publishing: 25] [Article Influence: 0.6] [Reference Citation Analysis]
28 Gutschner T, Hämmerle M, Pazaitis N, Bley N, Fiskin E, Uckelmann H, Heim A, Groβ M, Hofmann N, Geffers R, Skawran B, Longerich T, Breuhahn K, Schirmacher P, Mühleck B, Hüttelmaier S, Diederichs S. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma. Hepatology 2014;59:1900-11. [PMID: 24395596 DOI: 10.1002/hep.26997] [Cited by in Crossref: 95] [Cited by in F6Publishing: 81] [Article Influence: 13.6] [Reference Citation Analysis]
29 Aktas S, Karakayali H, Moray G, Ozdemir H, Haberal M. Effects of Risk Factors and Ki-67 on Rates of Recurrence on Patients Who Have Undergone Liver Transplant for Hepatocellular Carcinoma. Transplantation Proceedings 2011;43:3807-12. [DOI: 10.1016/j.transproceed.2011.09.067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
30 Park J, Lee K, Kim S, Choi S, Heo J, Kwon C, Kim D, Han Y, Lee S, Joh J. Outcome of Patients With Recurrent Hepatocellular Carcinoma in Liver Transplantation. Transplantation Proceedings 2006;38:2121-2. [DOI: 10.1016/j.transproceed.2006.06.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
31 Xie X, Wei M, Kakehashi A, Yamano S, Tajiri M, Wanibuchi H. 2-Amino-3-Methylimidazo[4,5-f]Quinoline (IQ) Promotes Mouse Hepatocarcinogenesis by Activating Transforming Growth Factor-  and Wnt/ -Catenin Signaling Pathways. Toxicological Sciences 2012;125:392-400. [DOI: 10.1093/toxsci/kfr314] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
32 Pereira CS, Oliveira MVMD, Fraga CADC, Barros LO, Domingos PLB, Roy A, De-paula AMB, Guimarães ALS. Impact of the epithelial dysplasia grading and Ki67 proliferation index in the adjacent non-malignant mucosa on recurrence and survival in head and neck squamous cell carcinoma. Pathology - Research and Practice 2012;208:651-6. [DOI: 10.1016/j.prp.2012.08.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
33 Liu J, Ma Q, Zhang M, Wang X, Zhang D, Li W, Wang F, Wu E. Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis. Eur J Cancer. 2012;48:2328-2338. [PMID: 22459764 DOI: 10.1016/j.ejca.2012.03.001] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 6.3] [Reference Citation Analysis]
34 Kajdacsy-balla A, Geynisman JM, Macias V, Setty S, Nanaji NM, Berman JJ, Dobbin K, Melamed J, Kong X, Bosland M, Orenstein J, Bayerl J, Becich MJ, Dhir R, Datta MW; The Cooperative Prostate Cancer Tissue Resource. Practical aspects of planning, building, and interpreting tissue microarrays: The Cooperative Prostate Cancer Tissue Resource experience. J Mol Hist 2007;38:113-21. [DOI: 10.1007/s10735-006-9054-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
35 Kneteman N, Livraghi T, Madoff D, de Santibañez E, Kew M. Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation: Monitoring Patients with Hepatocellular Carcinoma. Liver Transpl 2011;17:S117-27. [DOI: 10.1002/lt.22334] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
36 Xin H, Wang K, Hu G, Xie F, Ouyang K, Tang X, Wang M, Wen D, Zhu Y, Qin X. Establishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenografts. PLoS One 2014;9:e85308. [PMID: 24416385 DOI: 10.1371/journal.pone.0085308] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
37 Lee SH, Lee JS, Na GH, You YK, Kim DG. Immunohistochemical markers for hepatocellular carcinoma prognosis after liver resection and liver transplantation. Clin Transplant. 2017;31. [PMID: 27653235 DOI: 10.1111/ctr.12852] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
38 Hübscher SG. Recurrent and de-novo disease in the liver allograft: . Current Opinion in Organ Transplantation 2006;11:283-8. [DOI: 10.1097/01.mot.0000227847.59947.8d] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
39 She WH, Chan ACY, Cheung TT, Lo CM, Chok KSH. Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels. World J Hepatol. 2018;10:308-318. [PMID: 29527266 DOI: 10.4254/wjh.v10.i2.308] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
40 Singhal A, Jayaraman M, Dhanasekaran DN, Kohli V. Molecular and serum markers in hepatocellular carcinoma: Predictive tools for prognosis and recurrence. Critical Reviews in Oncology/Hematology 2012;82:116-40. [DOI: 10.1016/j.critrevonc.2011.05.005] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 5.7] [Reference Citation Analysis]
41 Fahrner R, Dondorf F, Ardelt M, Dittmar Y, Settmacher U, Rauchfuß F. Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival. World J Gastroenterol 2015;21:12071-82. [PMID: 26576092 DOI: 10.3748/wjg.v21.i42.12071] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
42 Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer. 2007;43:979-992. [PMID: 17291746 DOI: 10.1016/j.ejca.2007.01.004] [Cited by in Crossref: 171] [Cited by in F6Publishing: 149] [Article Influence: 12.2] [Reference Citation Analysis]
43 Ye Z, Cao L, Wei Y, Chen J, Zhang Z, Yao S, Duan T, Song B. Preoperative prediction of hepatocellular carcinoma with highly aggressive characteristics using quantitative parameters derived from hepatobiliary phase MR images. Ann Transl Med 2020;8:85. [PMID: 32175378 DOI: 10.21037/atm.2020.01.04] [Reference Citation Analysis]
44 Gurakar A, Ma M, Garonzik-wang J, Kim A, Anders RA, Oshima K, Georgiades C, Gurakar M, Ottmann S, Cameron AM, Philosophe B, Saberi B. Clinicopathological Distinction of Low-AFP-Secreting vs. High-AFP-Secreting Hepatocellular Carcinomas. Annals of Hepatology 2018;17:1052-66. [DOI: 10.5604/01.3001.0012.7206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]